Tecovirimat Resistance in Mpox Patients, United States, 2022-2023.
ST-246
TPOXX
United States
antimicrobial resistance
antivirals
monkeypox virus
mpox
orthopoxvirus
tecovirimat
viruses
Journal
Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
medline:
21
11
2023
pubmed:
19
10
2023
entrez:
19
10
2023
Statut:
ppublish
Résumé
During the 2022 multinational outbreak of monkeypox virus (MPXV) infection, the antiviral drug tecovirimat (TPOXX; SIGA Technologies, Inc., https://www.siga.com) was deployed in the United States on a large scale for the first time. The MPXV F13L gene homologue encodes the target of tecovirimat, and single amino acid changes in F13 are known to cause resistance to tecovirimat. Genomic sequencing identified 11 mutations previously reported to cause resistance, along with 13 novel mutations. Resistant phenotype was determined using a viral cytopathic effect assay. We tested 124 isolates from 68 patients; 96 isolates from 46 patients were found to have a resistant phenotype. Most resistant isolates were associated with severely immunocompromised mpox patients on multiple courses of tecovirimat treatment, whereas most isolates identified by routine surveillance of patients not treated with tecovirimat remained sensitive. The frequency of resistant viruses remains relatively low (<1%) compared with the total number of patients treated with tecovirimat.
Identifiants
pubmed: 37856204
doi: 10.3201/eid2912.231146
pmc: PMC10683829
doi:
Substances chimiques
Antiviral Agents
0
Benzamides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2426-2432Références
Proc Natl Acad Sci U S A. 2010 Jan 12;107(2):838-43
pubmed: 20080762
Ann Intern Med. 2023 Aug;176(8):1141-1143
pubmed: 37487213
Antiviral Res. 2013 Mar;97(3):301-11
pubmed: 23257396
Antimicrob Agents Chemother. 2009 Mar;53(3):1007-12
pubmed: 19075062
Antivir Ther. 2007;12(8):1205-16
pubmed: 18240860
Antimicrob Agents Chemother. 2009 Dec;53(12):4999-5009
pubmed: 19752270
J Virol. 2005 Oct;79(20):13139-49
pubmed: 16189015
J Antimicrob Chemother. 2015 May;70(5):1367-80
pubmed: 25630650
Am J Trop Med Hyg. 2007 Apr;76(4):768-73
pubmed: 17426185
Nat Microbiol. 2022 Dec;7(12):1951-1955
pubmed: 36344621
N Engl J Med. 2023 Mar 30;388(13):1246-1247
pubmed: 36884032
Lancet Infect Dis. 2023 Jun;23(6):e218-e226
pubmed: 36773621
Antimicrob Agents Chemother. 2009 Jun;53(6):2620-5
pubmed: 19349521
Antimicrob Agents Chemother. 2009 May;53(5):1817-22
pubmed: 19223621
MMWR Morb Mortal Wkly Rep. 2023 Mar 03;72(9):232-243
pubmed: 36862595
MMWR Morb Mortal Wkly Rep. 2022 Jun 10;71(23):764-769
pubmed: 35679181
Antimicrob Agents Chemother. 2007 Feb;51(2):689-95
pubmed: 17116683
Antiviral Res. 2008 Aug;79(2):121-7
pubmed: 18479761
Sci Transl Med. 2022 Nov 30;14(673):eade7646
pubmed: 36318038
J Virol. 2013 May;87(10):5564-76
pubmed: 23468500
N Engl J Med. 2023 Jan 19;388(3):279-281
pubmed: 36577096
Science. 2022 Nov 4;378(6619):560-565
pubmed: 36264825
Transpl Infect Dis. 2023 Feb;25(1):e14022
pubmed: 36714983
J Virol. 2011 Sep;85(17):9176-87
pubmed: 21697474
J Infect Dis. 2012 Nov;206(9):1372-85
pubmed: 22904336
Antimicrob Agents Chemother. 2023 Oct 12;:e0097223
pubmed: 37823631
Antimicrob Agents Chemother. 2023 Jun 20;67(7):e0056823
pubmed: 37338408
Antiviral Res. 2019 Aug;168:168-174
pubmed: 31181284
Antimicrob Agents Chemother. 2013 Dec;57(12):6246-53
pubmed: 24100494